Literature DB >> 20543106

The relative timing of exposure to phagocytosable particulates and to osteoclastogenic cytokines is critically important in the determination of myeloid cell fate.

Douglas E James1, Bryan J Nestor, Thomas P Sculco, Lionel B Ivashkiv, F Patrick Ross, Steven R Goldring, P Edward Purdue.   

Abstract

During granulomatous inflammatory reactions, myeloid cells can differentiate into activated phagocytic macrophages, wound-healing macrophages, foreign body giant cells, and bone-resorbing osteoclasts. Although it is appreciated that a variety of stimuli, including cytokines, cell-matrix interactions, and challenge with foreign materials can influence myeloid cell fate, little is known of how these signals integrate during this process. In this study, we have investigated the cross talk between receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis and particle phagocytosis-induced activation of human monocytes. Understanding interconnected signals is of particular importance to disorders, such as periprosthetic osteolysis, in which granulomatous inflammation is initiated by particle phagocytosis in proximity to bone and leads to inflammatory bone loss. Using cell-based osteoclastogenesis and phagocytosis assays together with expression analysis of key regulators of osteoclastogenesis, we show in this study that phagocytosis of disease-relevant particles inhibits RANKL-mediated osteoclastogenesis of human monocytes. Mechanistically, phagocytosis mediates this effect by downregulation of RANK and c-Fms, the receptors for the essential osteoclastogenic cytokines RANKL and M-CSF. RANKL pretreatment of monocytes generates preosteoclasts that are resistant to RANK downregulation and committed to osteoclast formation, even though they retain phagocytic activity. Thus, the relative timing of exposure to phagocytosable particulates and to osteoclastogenic cytokines is critically important in the determination of myeloid cell fate.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543106      PMCID: PMC3016856          DOI: 10.4049/jimmunol.0902808

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Involvement of complement receptor 3 (CR3) and scavenger receptor in macrophage responses to wear debris.

Authors:  Diptendu S Rakshit; Jin T E Lim; Khanh Ly; Lionel B Ivashkiv; Bryan J Nestor; Thomas P Sculco; P Edward Purdue
Journal:  J Orthop Res       Date:  2006-11       Impact factor: 3.494

2.  Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-kappa B ligand.

Authors:  Ayako Mochizuki; Masamichi Takami; Tadaharu Kawawa; Reina Suzumoto; Takahisa Sasaki; Akihiko Shiba; Hiroaki Tsukasaki; Baohong Zhao; Rika Yasuhara; Tetsuo Suzawa; Yoichi Miyamoto; Yongwon Choi; Ryutaro Kamijo
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

Review 3.  The cellular and molecular biology of periprosthetic osteolysis.

Authors:  P Edward Purdue; Panagiotis Koulouvaris; Hollis G Potter; Bryan J Nestor; Thomas P Sculco
Journal:  Clin Orthop Relat Res       Date:  2007-01       Impact factor: 4.176

4.  Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis.

Authors:  Diptendu S Rakshit; Khanh Ly; Tapas K Sengupta; Bryan J Nestor; Thomas P Sculco; Lionel B Ivashkiv; P Edward Purdue
Journal:  J Bone Joint Surg Am       Date:  2006-04       Impact factor: 5.284

5.  v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation.

Authors:  Seoung-Hoon Lee; Jaerang Rho; Daewon Jeong; Jai-Yoon Sul; Taesoo Kim; Nacksung Kim; Ju-Seob Kang; Takeshi Miyamoto; Toshio Suda; Sun-Kyeong Lee; Robert J Pignolo; Boguslawa Koczon-Jaremko; Joseph Lorenzo; Yongwon Choi
Journal:  Nat Med       Date:  2006-11-26       Impact factor: 53.440

6.  Stimulation by TLR5 modulates osteoclast differentiation through STAT1/IFN-beta.

Authors:  Hyunil Ha; Jong-Ho Lee; Ha-Neui Kim; Han Bok Kwak; Hyun-Man Kim; Shee Eun Lee; Joon Haeng Rhee; Hong-Hee Kim; Zang Hee Lee
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

7.  Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis.

Authors:  Panagiotis Koulouvaris; Khanh Ly; Lionel B Ivashkiv; Mathias P Bostrom; Bryan J Nestor; Thomas P Sculco; P Edward Purdue
Journal:  J Orthop Res       Date:  2008-01       Impact factor: 3.494

8.  NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).

Authors:  Kabsun Kim; Seoung-Hoon Lee; Jung Ha Kim; Yongwon Choi; Nacksung Kim
Journal:  Mol Endocrinol       Date:  2007-09-20

9.  NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis.

Authors:  Yasuhiro Yamanaka; Wahid Abu-Amer; Dominica Foglia; Jesse Otero; John C Clohisy; Yousef Abu-Amer
Journal:  J Orthop Res       Date:  2008-12       Impact factor: 3.494

10.  The role played by cell-substrate interactions in the pathogenesis of osteoclast-mediated peri-implant osteolysis.

Authors:  Zhenxin Shen; Tania N Crotti; Kevin P McHugh; Kenichiro Matsuzaki; Ellen M Gravallese; Benjamin E Bierbaum; Steven R Goldring
Journal:  Arthritis Res Ther       Date:  2006-04-13       Impact factor: 5.156

View more
  5 in total

Review 1.  Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8.

Authors:  Lionel B Ivashkiv; Baohong Zhao; Kyung-Hyun Park-Min; Masamichi Takami
Journal:  Ann N Y Acad Sci       Date:  2011-11       Impact factor: 5.691

2.  Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal.

Authors:  Abhishek D Garg; Sanne Elsen; Dmitri V Krysko; Peter Vandenabeele; Peter de Witte; Patrizia Agostinis
Journal:  Oncotarget       Date:  2015-09-29

3.  Genome-Wide Association Identifies Risk Pathways for SAPHO Syndrome.

Authors:  Ruikun Cai; Yichao Dong; Mingxia Fang; Yuxuan Fan; Zian Cheng; Yue Zhou; Jianen Gao; Feifei Han; Changlong Guo; Xu Ma
Journal:  Front Cell Dev Biol       Date:  2021-03-18

4.  Rho GTPase expression in human myeloid cells.

Authors:  Suzanne F G van Helden; Eloise C Anthony; Rob Dee; Peter L Hordijk
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

5.  Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy.

Authors:  Matthew R Steensma; Wakenda K Tyler; Allison G Shaber; Steven R Goldring; F Patrick Ross; Bart O Williams; John H Healey; P Edward Purdue
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.